Matrixx Eyes Antacids, Oral Care; Zicam Brand Drives 50% Sales Jump
This article was originally published in The Tan Sheet
Executive Summary
Matrixx is concentrating research spending on antacids, analgesics and oral care as possible areas for new product development
You may also be interested in...
Slow Cold Season Trims Matrixx Q4 Sales, But Net Loss Down By $2.5 Million
A slow-starting cold season contributed to an 18 percent dip in fourth-quarter sales of Matrixx Initiatives' Zicam cough/cold and flu relief products, company President and CEO Carl Johnson says
Slow Cold Season Trims Matrixx Q4 Sales, But Net Loss Down By $2.5 Million
A slow-starting cold season contributed to an 18 percent dip in fourth-quarter sales of Matrixx Initiatives' Zicam cough/cold and flu relief products, company President and CEO Carl Johnson says
Slow Cold Season Trims Matrixx Q4 Sales, But Net Loss Down By $2.5 Million
A slow-starting cold season contributed to an 18 percent dip in fourth-quarter sales of Matrixx Initiatives' Zicam cough/cold and flu relief products, company President and CEO Carl Johnson says